Inhibiting mutant FGFR2 in endometrial cancer by extracellular blockade

子宫内膜癌是女性常见的妇科癌症，需要新的治疗方法来提高存活率。我们已经确定了一种关键细胞膜蛋白(FGFR2)的突变，并表明具有这些突变的子宫内膜癌细胞改变了对生长因子的依赖。抑制这些突变蛋白可能导致细胞死亡。通过表征这些突变及其对细胞的影响，我们将能够开发特定的阻滞剂，用于潜在的新型治疗

Endometrial cancer is a common gynecological cancer in women and new therapies are required to improve survival rates. We have identified mutations in a key cell membrane protein (FGFR2) and shown that endometrial cancer cells with these mutations have altered growth factor dependence. Inhibiting these mutant proteins can result in cell death. By characterizing these mutations and their cellular effects we will be able to develop specific blocking agents for use as potential novel treatments